Harmonization of Dementia Drug Guidelines (United States and Europe): a report of the International Working Group for the Harmonization for Dementia Drug Guidelines.
The International Working Group for the Harmonization of Dementia Drug Guidelines has been active for more than 5 years attempting to improve the efficiency of international drug development. A virtual organization was formed of clinicians, scientists, industries, participants, and regulators from various nations around the world. This article summarizes a variety of conferences and physicians' papers focusing on aspects of trials ranging from diagnosis, assessment, and trial design to pharmacoeconomics and ethics.
Whitehouse
P J
PJ
Case Western Reserve and University Hospitals of Cleveland at Fairhill Center for Aging, Ohio, USA.
D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D016527:Drug Costs; D015195:Drug Design; D017850:Economics, Pharmaceutical; D004992:Ethics, Medical; D005060:Europe; D006801:Humans; D007391:International Cooperation; D007400:Interprofessional Relations; D017410:Practice Guidelines as Topic; D012107:Research Design; D014481:United States